证券代码：688176 证券简称：亚虹医药 公告编号：2025-026 江苏亚虹医药科技股份有限公司 关于使用剩余超募资金永久补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏亚虹医药科技股份有限公司（以下简称"公司"）于 2025 年 6 月 27 日 召开第二届董事会第十七次会议、第二届监事会第十三次会议，审议通过《关于 使用剩余超募资金永久补充流动资金的议案》，同意公司使用剩余超募资金总计 人民币 8,704.07 万元（含已到期利息收入及理财收益，实际金额以资金转出当日 专户余额为准）用于永久补充流动资金。本次使用剩余超募资金永久补充流动资 金不会影响投资项目建设的资金需求，在补充流动资金后的十二个月内不进行高 风险投资以及为控股子公司以外的对象提供财务资助。本次使用剩余超募资金永 久补充流动资金后，公司首次公开发行超募资金账户余额为人民币 0 元，公司将 按照相关规定注销相关募集资金专用账户。中信证券股份有限公司（以下简称"保 荐人"）对本事项出具了明确的核查意见，该事项尚需提交公司股东大会 ...

证券代码：688176 证券简称：亚虹医药 公告编号：2025-025 江苏亚虹医药科技股份有限公司 第二届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 江苏亚虹医药科技股份有限公司（以下简称"公司"）第二届监事会第十三 次会议通知于 2025 年 6 月 20 日以邮件等方式送达全体监事，会议于 2025 年 6 月 27 日在公司会议室以现场参会方式召开。本次会议由监事会主席钟毅先生召 集并主持，应到监事 3 人，实到监事 3 人，出席监事占应出席人数的 100%。本 次会议的召集和召开程序符合《中华人民共和国公司法》等法律法规、规范性文 件以及《江苏亚虹医药科技股份有限公司章程》的相关规定，会议形成的决议合 法、有效。 经审议，监事会认为：此次使用剩余超募资金用于永久补充流动资金符合《上 市公司募集资金监管规则》及修订说明、《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》等法律法规、规范性文件以及《江苏亚虹医药科 技股份有限公司章程》的相关规定 ...

Meeting Overview - The second meeting of the Supervisory Board of Jiangsu Yahon Pharmaceutical Technology Co., Ltd. was held on June 20, 2025, with full attendance of all three supervisors [1]. Resolutions Passed - The Supervisory Board approved the proposal to annul part of the restricted stock from the 2022 incentive plan that had been granted but not yet vested, confirming compliance with relevant laws and regulations [1][2]. - The Board also approved the conditions for the second vesting period of the initial grant and the first vesting period of the reserved grant under the 2022 incentive plan, stating that the conditions had been met [2][3]. - The company agreed to provide guarantees for its wholly-owned subsidiaries, Shanghai Yahon Pharmaceutical Technology Co., Ltd. and Hainan Yahon Pharmaceutical Trading Co., Ltd., for a total bank credit limit not exceeding RMB 150 million, which represents 7.62% of the company's latest audited net assets [3].

Core Viewpoint - Jiangsu Yahon Pharmaceutical Technology Co., Ltd. has announced the cancellation of 1.8305 million shares of restricted stock that were granted but not yet vested under the 2022 Restricted Stock Incentive Plan [1][6] Summary by Sections Approval Procedures - The board of directors approved the incentive plan and related matters during meetings held on July 27, 2022, and subsequent meetings [2][3][4] - The supervisory board verified the incentive plan and provided relevant opinions [2][5] Cancellation Details - The cancellation of the restricted stock is due to 8 incentive recipients leaving the company, resulting in 1.6888 million shares being forfeited, and 4 recipients failing to meet performance criteria, leading to an additional 0.1304 million shares being canceled [6] - In total, 1.8305 million shares of restricted stock will be canceled [6] Impact on the Company - The cancellation of the restricted stock will not have a substantial impact on the company's financial status or operational results, nor will it affect the stability of the management team or the implementation of the incentive plan [6] Supervisory Board Opinion - The supervisory board agrees that the cancellation of the restricted stock complies with relevant laws and regulations and does not harm shareholder interests [6] Legal and Financial Advisor Opinions - Legal opinions confirm that the cancellation is in accordance with the Company Law, Securities Law, and relevant regulations [6] - The independent financial advisor supports that the cancellation has received necessary approvals and does not harm the interests of the company or its shareholders [6]

Summary of Key Points Core Viewpoint - The company plans to provide a guarantee of up to RMB 150 million for its wholly-owned subsidiaries, Shanghai Yahuang and Hainan Yahuang, to meet their funding needs for business operations, which represents 7.62% of the company's latest audited net assets [1][6]. Group 1: Guarantee Details - The guarantee will be in the form of joint liability guarantee and the specific terms will be defined in the actual guarantee contract [6]. - The board of directors approved the guarantee proposal on June 20, 2025, and it does not require submission to the shareholders' meeting for approval [1][6]. Group 2: Subsidiary Information - Shanghai Yahuang was established on November 17, 2017, with a registered capital of RMB 50 million and is 100% owned by the company [3]. - Hainan Yahuang was established on March 17, 2022, with a registered capital of RMB 10 million and is also 100% owned by the company [4][5]. Group 3: Financial Data - Shanghai Yahuang's total assets are RMB 317.45 million, total liabilities are RMB 975.44 million, and net assets are -RMB 657.99 million, with a revenue of RMB 0.0197 million and a net loss of RMB 204.81 million [2]. - Hainan Yahuang's total assets are RMB 107.26 million, total liabilities are RMB 157.27 million, and net assets are -RMB 50.01 million, with a revenue of RMB 174.98 million and a net loss of RMB 40.97 million [5]. Group 4: Rationale for Guarantee - The guarantee is intended to enhance the financing efficiency of the subsidiaries, ensuring their operational needs are met and aligning with the overall interests of the company [6]. - The company maintains absolute control over its subsidiaries, allowing for effective monitoring of their operations and financial usage, thus keeping the guarantee risk manageable [6]. Group 5: Board and Sponsor Opinions - The board believes that the guarantee aligns with the operational needs of the company and its subsidiaries, poses controllable risks, and does not harm the interests of the company or minority shareholders [6]. - The sponsor has confirmed that the decision-making process for the guarantee complies with relevant regulations and does not harm the interests of the company and its shareholders [7][8].

Core Points - Jiang Xinming has resigned from his position as a director and a member of the audit committee of Jiangsu Yahon Pharmaceutical Technology Co., Ltd due to work adjustments, but will continue to hold another position within the company [1][2][3] - The resignation will take effect after the election of a new director at the company's shareholders' meeting, as the current audit committee will have fewer than three members [2][3] - The company expresses gratitude for Jiang Xinming's contributions during his tenure [3] Summary of Changes - Jiang Xinming's resignation details: He held approximately 898,500 shares, representing about 0.16% of the total share capital [3] - Xu Ying has been proposed as a candidate for the board of directors and will serve until the end of the current board's term [3][5] - The audit committee will now include Zhang Binghui as the chairman and members Wang Wenning and Xu Ying [5] Background of New Director - Xu Ying, born in 1968, has extensive experience in the pharmaceutical industry, having held various senior positions in companies such as GlaxoSmithKline and Pfizer [7] - Xu Ying indirectly holds approximately 500,100 shares, accounting for about 0.09% of the total share capital [8] - Xu Ying meets all legal and regulatory requirements to serve as a director and has no disqualifications or negative records [8]

一、本次激励计划批准及实施情况 证券代码：688176 证券简称：亚虹医药 公告编号：2025-022 （一）本次激励计划方案及履行的程序 （2）授予数量：本次激励计划向激励对象授予的限制性股票数量为 979.08 万股，约占本次激励计划草案公告时公司股本总额 57,000 万股的 1.72%。其中首 江苏亚虹医药科技股份有限公司 关于 2022 年限制性股票激励计划首次授予部分 第二个归属期及预留授予部分第一个归属期 符合归属条件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司于 2025 年 6 月 20 日召开第二届董事会第十六次会议和第二届监事会第 十二次会议，审议通过了《关于 2022 年限制性股票激励计划首次授予部分第二 个归属期及预留授予部分第一个归属期符合归属条件的议案》，公司 2022 年限 制性股票激励计划（以下简称"本次激励计划"或《激励计划》）首次授予部分 第二个归属期及预留授予部分第一个归属期归属条件已经成就。现将有关事项说 明如下： 1 限制性股票拟归属数量：162. ...

江苏亚虹医药科技股份有限公司 关于作废 2022 年限制性股票激励计划部分已授予但 尚未归属的限制性股票的公告 证券代码：688176 证券简称：亚虹医药 公告编号：2025-021 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏亚虹医药科技股份有限公司（以下简称"公司"或"亚虹医药"）于 2025 年 6 月 20 日召开了第二届董事会第十六次会议、第二届监事会第十二次会 议，审议通过了《关于作废 2022 年限制性股票激励计划部分已授予但尚未归属 的限制性股票的议案》。根据《江苏亚虹医药科技股份有限公司 2022 年限制性 股票激励计划》（以下简称"《激励计划》"或"本次激励计划"）、《江苏亚 虹医药科技股份有限公司 2022 年限制性股票激励计划实施考核管理办法》的规 定和公司 2022 年第一次临时股东大会的授权，公司董事会同意作废部分已授予 但尚未归属的限制性股票共计 183.05 万股。现将有关事项说明如下： 一、本次股权激励计划已履行的相关审批程序 （一）2022 年 7 月 27 日，公司召开第一届董 ...

北京市嘉源律师事务所 关于江苏亚虹医药科技股份有限公司 2022 年限制性股票激励计划 首次授予第二个归属期 及预留授予第一个归属期归属条件成就 暨部分限制性股票作废事项的法律意见书 务所 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 REUTERS In YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:江苏亚虹医药科技股份有限公司 北京市嘉源律师事务所 关于江苏亚虹医药科技股份有限公司 2022 年限制性股票激励计划 首次授予第二个归属期 及预留授予第一个归属期符合归属条件 暨部分限制性股票作废事项的法律意见书 嘉源(2025)-05-207 嘉源 ·法律意见书 询问并进行了必要的讨论。 在前述调查过程中,本所得到公司如下保证:公司已提供了本所认为出具本 法律意见书必需的、真实、准确、完整的原始书面材料、副本材料或口头证言, 不存在任何遗漏或隐瞒;其所提供的所有文件及所述事实均为真实、准确和完整; 公司所提供的文件及文件上的签名和印章均是真实 ...

证券简称：亚虹医药 证券代码：688176 上海荣正企业咨询服务（集团）股份有限公司 关于 江苏亚虹医药科技股份有限公司 2022 年限制性股票激励计划 首次授予部分第二个归属期及预留授予部分第一个 归属期归属条件成就相关事项 之 独立财务顾问报告 2025 年 6 月 | 3 | 一、释义 | | --- | --- | | 4 | 二、声明 | | 三、基本假设 5 | | | 四、独立财务顾问意见 6 | | | 五、备查文件及咨询方式 14 | | 一、释义 1. 上市公司、公司、亚虹医药：指江苏亚虹医药科技股份有限公司。 2. 股权激励计划、限制性股票激励计划、本激励计划、本次激励计划、《激励 计划》、本计划：指《江苏亚虹医药科技股份有限公司 2022 年限制性股票激励 计划》。 3. 限制性股票、第二类限制性股票：指符合本激励计划授予条件的激励对象， 在满足相应归属条件后分次获得并登记的公司股票。 4. 股本总额：指公司股东大会审议通过本计划时公司已发行的股本总额。 5. 激励对象：指按照本激励计划规定，获得限制性股票的董事、高级管理人 员、核心技术人员及董事会认为需要激励的其他人员。 6. 授予 ...